Pharmacokinetics of levetiracetam.
Publication
, Journal Article
Radtke, RA
Published in: Epilepsia
2001
Major considerations in the acceptance and impact of new antiepileptic drugs include their pharmacokinetics and their potential for interaction with other drugs. The pharmacokinetics of levetiracetam, a newly approved add-on antiepileptic agent for partial-onset seizures in adults, has been evaluated in 27 phase I and II studies. Consistent findings in these studies include rapid and complete oral absorption, linear dose kinetics, a minimal degree of protein binding, and predominantly renal excretion. Because of the lack of hepatic metabolism and low protein binding, the risk of interaction with other drugs is considered low.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Epilepsia
DOI
ISSN
0013-9580
Publication Date
2001
Volume
42 Suppl 4
Start / End Page
24 / 27
Location
United States
Related Subject Headings
- Piracetam
- Neurology & Neurosurgery
- Levetiracetam
- Humans
- Half-Life
- Epilepsy
- Drug Therapy, Combination
- Drug Interactions
- Drug Administration Schedule
- Clinical Trials as Topic
Citation
APA
Chicago
ICMJE
MLA
NLM
Radtke, R. A. (2001). Pharmacokinetics of levetiracetam. Epilepsia, 42 Suppl 4, 24–27. https://doi.org/10.1046/j.1528-1157.2001.0420s4024.x
Radtke, R. A. “Pharmacokinetics of levetiracetam.” Epilepsia 42 Suppl 4 (2001): 24–27. https://doi.org/10.1046/j.1528-1157.2001.0420s4024.x.
Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia. 2001;42 Suppl 4:24–7.
Radtke, R. A. “Pharmacokinetics of levetiracetam.” Epilepsia, vol. 42 Suppl 4, 2001, pp. 24–27. Pubmed, doi:10.1046/j.1528-1157.2001.0420s4024.x.
Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia. 2001;42 Suppl 4:24–27.
Published In
Epilepsia
DOI
ISSN
0013-9580
Publication Date
2001
Volume
42 Suppl 4
Start / End Page
24 / 27
Location
United States
Related Subject Headings
- Piracetam
- Neurology & Neurosurgery
- Levetiracetam
- Humans
- Half-Life
- Epilepsy
- Drug Therapy, Combination
- Drug Interactions
- Drug Administration Schedule
- Clinical Trials as Topic